Literature DB >> 1943686

Non-random distribution of missense mutations within the human tyrosinase gene in type I (tyrosinase-related) oculocutaneous albinism.

R A King1, M M Mentink, W S Oetting.   

Abstract

Type I oculocutaneous albinism (OCA) is produced by mutations of the tyrosinase gene. We report four new missense mutations in the tyrosinase gene in patients with type IA OCA. Three of these mutations occur within exon I and the fourth mutation within exon IV. Analysis of the distribution of these four missense mutations and 12 previously reported missense mutations shows that most cluster in four areas of the gene. Two clusters involve the copper A and copper B binding sites and could disrupt the metal ion-protein interaction necessary for enzyme function. The other two clusters are in exon I and exon IV and could represent important functional domains of the enzyme. We conclude that analysis of the tyrosinase missense mutations will provide insight into the structure-function relationship of this enzyme.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1943686

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  17 in total

1.  The molecular basis of oculocutaneous albinism type 1 (OCA1): sorting failure and degradation of mutant tyrosinases results in a lack of pigmentation.

Authors:  K Toyofuku; I Wada; R A Spritz; V J Hearing
Journal:  Biochem J       Date:  2001-04-15       Impact factor: 3.857

2.  An MboI polymorphism at codon 192 of the human tyrosinase gene is present in Asians and Afrocaribbeans.

Authors:  J D Johnston; A F Winder; L H Breimer
Journal:  Nucleic Acids Res       Date:  1992-03-25       Impact factor: 16.971

3.  Mutation in and lack of expression of tyrosinase-related protein-1 (TRP-1) in melanocytes from an individual with brown oculocutaneous albinism: a new subtype of albinism classified as "OCA3".

Authors:  R E Boissy; H Zhao; W S Oetting; L M Austin; S C Wildenberg; Y L Boissy; Y Zhao; R A Sturm; V J Hearing; R A King; J J Nordlund
Journal:  Am J Hum Genet       Date:  1996-06       Impact factor: 11.025

Review 4.  Copper active sites in biology.

Authors:  Edward I Solomon; David E Heppner; Esther M Johnston; Jake W Ginsbach; Jordi Cirera; Munzarin Qayyum; Matthew T Kieber-Emmons; Christian H Kjaergaard; Ryan G Hadt; Li Tian
Journal:  Chem Rev       Date:  2014-03-03       Impact factor: 60.622

5.  Molecular analyses of a tyrosinase-negative albino family.

Authors:  K C Park; C D Chintamaneni; R Halaban; C J Witkop; B S Kwon
Journal:  Am J Hum Genet       Date:  1993-02       Impact factor: 11.025

6.  Unraveling the melanocyte.

Authors:  V J Hearing
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

7.  A frequent tyrosinase gene mutation associated with type I-A (tyrosinase-negative) oculocutaneous albinism in Puerto Rico.

Authors:  W S Oetting; C J Witkop; S A Brown; R Colomer; J P Fryer; K E Bloom; R A King
Journal:  Am J Hum Genet       Date:  1993-01       Impact factor: 11.025

8.  Single-strand conformation polymorphism analysis of point mutation in a tyrosinase-negative oculocutaneous albinism.

Authors:  K C Park; K H Kim; Y S Lee; B S Kwon
Journal:  J Inherit Metab Dis       Date:  1994       Impact factor: 4.982

9.  Molecular and clinical characterization of albinism in a large cohort of Italian patients.

Authors:  Annagiusi Gargiulo; Francesco Testa; Settimio Rossi; Valentina Di Iorio; Simona Fecarotta; Teresa de Berardinis; Antonello Iovine; Adriano Magli; Sabrina Signorini; Elisa Fazzi; Maria Silvana Galantuomo; Maurizio Fossarello; Sandro Montefusco; Alfredo Ciccodicola; Alberto Neri; Claudio Macaluso; Francesca Simonelli; Enrico Maria Surace
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-03-14       Impact factor: 4.799

10.  Oculocutaneous albinism type 1: link between mutations, tyrosinase conformational stability, and enzymatic activity.

Authors:  Monika B Dolinska; Nicole J Kus; S Katie Farney; Paul T Wingfield; Brian P Brooks; Yuri V Sergeev
Journal:  Pigment Cell Melanoma Res       Date:  2017-01       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.